Chemical and Pharmaceutical Bulletin p. 1685 - 1693 (1999)
Update date:2022-08-05
Topics:
Ono, Shin'ichiro
Inoue, Yoshihisa
Yoshida, Tomohiro
Ashimori, Atsuyuki
Kosaka, Keigo
Imada, Teruaki
Fukaya, Chikara
Nakamura, Norifumi
The synthesis and design using molecular modeling techniques for non- peptide, low molecular weight novel fibrinogen receptor (glycoprotein IIb/IIIa: Gp IIb/IIIa) antagonists, is reported. We used a highly potent serine protease inhibitor, Nafamostat, having an amidinonaphthyl unit as the starting compound. The compounds 4-(6-amidino-2- naphthylaminocarbonyl)phenoxyacetic acid (5a) and 4-(6-amidino-2- naphthalenecarboxamido)phenoxyacetic acid (5b) inhibited adenosin-5'- diphospate (ADP)-induced aggregation of human platelet-rich plasma (PRP) with IC50 values of 0,05 and 0.07 μM, respectively, and had lost their ability to inhibit a variety of serine proteases, including thrombin, factor Xa, plasmin and trypsin.
View MoreNanjing Yuance Industry&Trade Co., Ltd.
website:http://www.njyuance.cn/
Contact:+86-25-85439097
Address:B1702, Aoti Bldg, No. 130, Aoti Avenue, Nanjing, China
Wuhan Fortuna Chemical Co.,Ltd
website:http://www.fortunachem.com
Contact:86-27-59207850
Address:Add: Room 2015, No.2 Building, Kaixin Mansion No.107 Jinqiao Avenue, Wuhan, China
Contact:+44 (0)161 367 9441
Address:
Nanjing Fubang Chemical Co.,Ltd
Contact:+86-25-83179199
Address:5F,Tianzheng international plaza,No399 Zhongyang Road ,Nanjing China
Zhengzhou Institute of Chiral Pharmer Research Co., Ltd.
Contact:86-371-55219111
Address:15 Floor, 2 Building, Central China Technovalley, Zhongyuan West Road
Doi:10.1246/bcsj.66.2931
(1993)Doi:10.1021/acs.orglett.5b01733
(2015)Doi:10.1021/ja00152a008
(1995)Doi:10.1002/asia.201402595
(2015)Doi:10.1021/ja00143a029
(1995)Doi:10.1055/s-1995-4026
(1995)
